N onaspirin nonsteroidal antiinflammatory drugs (NSAIDs) are one of the most commonly used medications during pregnancy (17%).
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Background:
The association between the use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy and the risk of spontaneous abortion remains unclear because of inconsistent research results and the lack of evidence for an effect due to specific types or dosages of nonaspirin NSAIDs. We aimed to quantify the association between having a spontaneous abortion and types and dosages of nonaspirin NSAIDs in a cohort of pregnant women.
Methods:
Using a nested case-control design, we obtained data from the Quebec Pregnancy Registry for 4705 women who had a spontaneous abortion. For each instance, we randomly selected 10 controls from the remaining women in the registry who were matched by index date (date of the spontaneous abortion) and gestational age. Use of nonaspirin NSAIDs (identified by filled prescriptions) and nonuse were compared. We also looked for associations between different types and dosages of nonaspirin NSAIDs and having a spontaneous abortion. Analyses of associations and adjustment for confounding were done using conditional logistic regression.
linked to those in three administrative databases: the Régie de l'assurance maladie du Québec (RAMQ) database, Med-Écho and the Institut de la statistique du Québec.
The RAMQ database contains prospectively collected information on medical services, filled prescriptions, physician-based diagnoses (according to the International Classification of Med-Écho is a provincial database that records data on admissions to acute care hospitals for all residents of Quebec. These data include the gestational ages (defined from the first day of the last menstrual period to the end of pregnancy, as confirmed by ultrasound) for planned and clinically detected spontaneous abortions and deliveries.
The Institut de la statistique du Québec database provides data on all births and deaths in Quebec, including birth weight and gestational age.
Women are followed in the Quebec Pregnancy Registry from the date of entry (the first day of the last menstrual period, as confirmed by ultrasound) until the end of pregnancy. Data recorded in these three databases have been validated previously. [8] [9] [10] Studies involving pregnant women insured by the RAMQ for their medications have been shown to generate valid risk estimates. 7 Our study was approved by the Centre hospitalier universitaire Ste -Justine Ethics Committee, and the linkage between databases was approved by the Commission d'accès à l'information du Québec.
Study population
We included all women who were 15-45 years old on the first day of gestation who were continuously insured by the RAMQ drug plan for at least 12 months before and during their pregnancies. Women who had a planned abortion, who had spontaneous abortions after 20 weeks' gestation or who had been exposed to misoprostol, NSAID suppositories or known teratogens before 20 weeks' gestation were exluded. For each individual woman, only her first pregnancy meeting our eligibility criteria was included.
Selection of cases and controls
Our case definition was a clinically detected spontaneous abortion occurring between the start of pregnancy and 20 weeks' gestation. Index date was defined as the calendar date of the clinically detected spontaneous abortions. Because we wished to assess several types of nonaspirin NSAIDs simultaneously, 10 controls were randomly selected for each case. Controls were selected from among pregnant women who did not have a spontaneous abortion at the same gestational age of their matched case, but who were at risk of having one, resulting in similar probabilities of exposure to medication. Controls were matched to the index date and gestational age of the case, because the risk of pregnancies ending in a loss is highly dependent on the gestational age at which the pregnancy is recognized.
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Exposure
We defined exposure to nonaspirin NSAIDs as either having filled at least one prescription for any type of nonaspirin NSAID between the start of pregnancy and the index date, or as having filled a prescription for a nonaspirin NSAID before pregnancy, the duration of which overlapped with the start of pregnancy. We only considered nonaspirin NSAIDs that were reimbursed by the RAMQ drug plan during the study period. Single exposure to nonaspirin NSAIDs was defined as having filled a prescription for at least one dose of only one type of nonaspirin NSAID between the start of pregnancy and the index date. Combination use of nonaspirin NSAIDs was defined as filling a prescription for at least one dose of two or more different nonaspirin NSAIDs from the same or different classes between the start of pregnancy and the index date. In all analyses, the reference category was defined as pregnant women not exposed to nonaspirin NSAIDs between the start of pregnancy and the index date.
In addition, we investigated the association between recent exposure to nonaspirin NSAIDs and the risk of spontaneous abortion using the two weeks immediately before the index date as our window for exposure. Finally, we examined the dose-response relationship by classifying women according to the overall percent maximum daily dose of nonaspirin NSAIDs they took between the start of pregnancy and the index date. These doses were subdivided into four clinically relevant categories: 1%-50%, 51%-65%, 66%-80% and 81% or more. Women who did not fill a prescription for a nonaspirin NSAID before their index date were considered not to have been exposed.
Confounding
We considered variables associated with both the exposure to nonaspirin NSAIDs and the risk of spontaneous abortion as potential confounders. 
Statistical analyses
To describe the study population, we presented means for continuous variables and proportions for dichotomous variables. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression and adjusted for the potential confounders described earlier. We conducted sensitivity analyses to evaluate whether our results were robust using a 60-day window of exposure to nonaspirin NSAIDs before the index date.
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Results
A total of 67 160 pregnant women met our inclusion criteria. Of those women, 4705 had a spontaneous abortion, to whom 47 050 controls were matched according to index date and gestational age. Overall, 352 women with a spontaneous abortion (7.5%) had filled one or more prescriptions for nonaspirin NSAIDs during pregnancy, compared with 1213 (2.6%) women among those who did not have a spontaneous abortion (p < 0.05).
Women who had a spontaneous abortion were slightly older, lived in an urban area, received social assistance and had more comorbidities in the 12 months before pregnancy than those who did not. In addition, women who had a spontaneous abortion used health care services more frequently in the year before pregnancy than those who did not (Table 1) . Moreover, women who had a spontaneous abortion had fewer prenatal visits and were taking more antidepressant, systemic anti -infective or other medications during pregnancy compared with women who did not. Naproxen was the most common nonaspirin NSAID used during pregnancy among women who had a spontaneous abortion ( Adjusting for potential confounders, use of nonaspirin NSAIDs during pregnancy was significantly associated with a 2.4-fold increase in the risk of spontaneous abortion (OR 2.43, 95% CI 2.12-2.79; 4705 cases, of which 352 were exposed) compared with nonuse (Table 3) . Analyzing exposure to nonaspirin NSAIDs in the two weeks immediately before the spontaneous abortion, we found that the risk was higher (OR 3.47, 95% CI 2.01-6.00; data not shown), although not significantly different from our previous overall estimate. All types of nonaspirin NSAIDs significantly increased the risk of spontaneous abortion ( Table 2 ). The highest risk was seen among women who used diclofenac alone (OR 3.09, 95% CI 1.96-4.87), whereas the lowest risk was seen among women who used rofecoxib alone (OR 1.83, 95% CI 1.24-2.70). However, no dose-response relationship was seen based on the overall percent maximum daily dose of nonaspirin NSAIDs (Table 2) .
Our sensitivity analysis based on a 60-day window of exposure resulted in the calculation of similar risk (data not shown).
Interpretation
Main findings
The use of nonaspirin NSAIDs during early pregnancy is associated with statistically significant risk (2.4-fold increase) of having a spontaneous abortion. We consistently saw that the risk of having a spontaneous abortion was associated with gestational use of diclofenac, naproxen, celecoxib, ibuprofen and rofecoxib alone or in combination, suggesting a class effect. We did not see a dose-response relationship.
Explanation and comparison with other studies
Our results agree with those of other studies involving human subjects. 3, 4 Indeed, our study agrees with Li and colleagues, who reported a risk of spontaneous abortion when nonaspirin NSAIDs were taken around the time of conception (hazard ratio [HR] 5.6, 95% CI 2.3-13.7). 4 However, our study did not replicate their finding that the association was even higher when exposure occurred immediately before the spontaneous abortion. 4 This may be because the use of nonaspirin NSAIDs immediately before spontaneous abortion was to relieve cramping, which is a precursor to the loss of pregnancy. If this were the case, exposure would occur after the event. This was not the case in our study, given that both of our estimates (use of nonaspirin NSAIDs at any time during pregnancy or in the two weeks immediately before spontaneous abortion) did not significantly differ from one another.
Although much remains unclear regarding the mechanism of action, prostaglandins play a putative role. The concentrations of prostaglandins in the human decidua during early pregnancy are lower than those in the endometrium at any stage of the menstrual cycle, primarily due to a decrease in the synthesis of prostaglandins. 11, 12 Data suggest that pregnancy is maintained by a mechanism that suppresses uterine synthesis of prostaglandins throughout gestation, and a defect in this inhibitory mechanism may be associated with early loss of pregnancy.
